Komori
Annual Securities Report4890Tsubota Laboratory IncorporatedPharmaceuticals

Annual Securities Report — FY2025

What Tsubota Laboratory Incorporated reported for the period from 2025-04-01 to 2026-03-31. Filed by 株式会社坪田ラボ

How much it says
62Detailed
What moved here
34named for the first time
Its own wording
61terms
Which filing this is
12/ 12newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

In the fiscal year ended 31 March 2026, revenue declined, while continued R&D investment resulted in an operating loss and net loss. The results also reflect the recognition of milestones and upfront fees for TLM-001, TLM-003 and TLM-017, as well as the assessment of a provision for contract losses relating to TLM-001.

Komori's summary of this document, not the document's own words.
62Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
Intensity of Change
70
Detailed
Strategic Shift
90
Very detailed
Capital Movements
62
Detailed
Disclosure Gaps
0
Almost nothing
Concentration Risk
68
Detailed
Change in Risk
71
Detailed
Financial and Capital Policy
69
Detailed
Specificity of Disclosure
60
Detailed
Product Portfolio
55
Typical
Technology Position
50
Typical
Confidence in Strategic Bets
R&D spend3億円Money spent making new things.
Cash left over-6億円Cash from the business, less what went into equipment.
Spent on equipment3百万円Plants, machines — things meant to last.
Employees22Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
Tsubota Laboratory Incorporated — FY2025 | Komori